Showing rec. 1 to 15 of 15
| Issue Date | Title | Author(s) |
| 2016 | Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy | BELLMUNT, JOAQUIM; ZHOU, CHENSHENG WILLA; MULLANE, STEPHANIE A, et al |
| 2017 | Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials | MOREIRA, RAPHAEL B.; Marcio Debiasi; FRANCINI, EDOARDO, et al |
| 2017 | Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials | MOREIRA, RAPHAEL B.; Marcio Debiasi; FRANCINI, EDOARDO, et al |
| 2020 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial | VAN DER HEIJDEN, MICHIEL S; GALSKY, MATTHEW D; PETRYLAK, DANIEL P, et al |
| 2017 | ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis | URUN, YUKSEL; LEOW, JEFFREY J.; André Poisl Fay, et al |
| 2015 | HER2 as a target in invasive urothelial carcinoma | BELLMUNT, JOAQUIM; WERNER, LILLIAN; BAMIAS, ARISTOTLE, et al |
| 2015 | HER2 as a target in invasive urothelial carcinoma | BELLMUNT, JOAQUIM; WERNER, LILLIAN; BAMIAS, ARISTOTLE, et al |
| 2015 | Is angiogenesis still an attractive target in metastatic castration-resistant prostate cancer? | André Poisl Fay; BELLMUNT, JOAQUIM |
| 2017 | Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model | DE VELASCO, GUILLERMO; CULHANE, AEDÍN C.; André Poisl Fay, et al |
| 2015 | Perioperative Therapy for Muscle Invasive Bladder Cancer | LEOW, JEFFREY J.; André Poisl Fay; MULLANE, STEPHANIE A., et al |
| 2015 | Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study | André Poisl Fay; SIGNORETTI, SABINA; CALLEA, MARCELLA, et al |
| 2015 | Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study | André Poisl Fay; SIGNORETTI, SABINA; CALLEA, MARCELLA, et al |
| 2015 | Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors | BELLMUNT, JOAQUIM; WERNER, LILLIAN; LEOW, JEFFREY J., et al |
| 2015 | Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors | BELLMUNT, JOAQUIM; WERNER, LILLIAN; LEOW, JEFFREY J., et al |
| 2016 | Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma | André Poisl Fay; DEVELASCO, GUILLERMO; Thai Ho, et al |
